You just read:

Phase 3 Data Show Daiichi Sankyo's Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer

News provided by

Daiichi Sankyo

Dec 09, 2013, 08:05 ET